75. クッシング病 Cushing disease Clinical trials / Disease details

臨床試験数 : 203 / 薬物数 : 191 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128

diseases per page:

Showing 1 to 10 of 203 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04569591 (ClinicalTrials.gov)	March 24, 2022	29/9/2020	Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in ...	Corticotrophin-Releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in ...	Cushing's Disease;Pituitary Adenoma	Drug: Acthrel	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Not yet recruiting	8 Years	N/A	All	22	N/A	United States
2	NCT04339751 (ClinicalTrials.gov)	March 24, 2022	8/4/2020	Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease	The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease	Cushing's Disease	Drug: Vorinostat	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Not yet recruiting	18 Years	N/A	All	22	Phase 2	United States
3	EUCTR2020-005605-93-IT (EUCTR)	21/12/2021	22/10/2021	Efficacy and safety of Silycus® in Cushing’s disease: a multicenter, single arm, openlabel, dose tit ...	Efficacy and safety of Silycus® in Cushing’s disease: a multicenter, single arm, openlabel, dose tit ...	Cushing's disease MedDRA version: 20.0;Level: SOC;Classification code 10014698;Term: Endocrine disor ...	Product Name: Silycus Product Code: [na]	ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	15	Phase 2	Italy
4	EUCTR2019-004019-29-IT (EUCTR)	15/07/2021	07/10/2020	Italian study to evaluate the efficacy of retinoic acid and cabergoline therapy in combination in Cu ...	Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: ...	Cushing's diseasein patients in whom pituitary surgery has not been curative or in situations where ...	Trade Name: Dostinex Product Name: Cabergolina Product Code: [G02CB03] INN or Proposed INN: CABERGOLINA ...	Dipartimento di Medicina-DIMED, università di Padova	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Italy
5	JPRN-jRCT1021210011	10/06/2021	10/06/2021	A diagnosis of pseudo-Cushing's syndrome using dexamethason/CHR and Alprazolam	A diagnosis of pseudo-Cushing's syndrome using dexamethason/CRH and anxiolytic Alprazolam	Pseudo Cushing's Syndrome Glucocorticoid , Stress, dexamethasone suppression test;D003480	In patients suspected of having Cushing's syndrome or pseudo-Cushing's syndrome, we perform two load ...	Asari Yuko	NULL	Recruiting	Not applicable	Not applicable	Both	100	Phase 2	Japan
6	EUCTR2018-001616-30-DE (EUCTR)	22/12/2020	16/03/2020	Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatmen ...	An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Sig ...	Endogenous CushingSyndrome MedDRA version: 24.0;Level: LLT;Classification code 10011657;Term: Cushin ...	Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHE ...	Corcept Therapeutics Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	75	Phase 2;Phase 3	United States;Hungary;Canada;Spain;Poland;Romania;Austria;Bulgaria;Israel;Netherlands;Germany;Italy
7	NCT04486859 (ClinicalTrials.gov)	December 1, 2020	22/7/2020	Postoperative Thrombosis Prevention in Patients With CD	A Prospective, Multicenter, Randomized Controlled Study of Postoperative Thrombosis Prevention in Pa ...	Cushing Disease;DVT;Pulmonary Embolism	Drug: LMWH/Rivaroxaban;Device: IPC	Huashan Hospital	Peking Union Medical College Hospital;West China Hospital	Recruiting	18 Years	60 Years	All	252	N/A	China
8	NCT03708900 (ClinicalTrials.gov)	October 30, 2020	8/10/2018	Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients Wi ...	A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmac ...	Cushing's Disease	Drug: LCI699	Novartis Pharmaceuticals	NULL	Recruiting	6 Years	18 Years	All	12	Phase 2	Belgium;Bulgaria;Italy;Slovenia;United Kingdom
9	EUCTR2018-001616-30-BG (EUCTR)	27/03/2020	24/02/2020	Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatmen ...	An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Sig ...	Endogenous CushingSyndrome MedDRA version: 24.0;Level: LLT;Classification code 10011657;Term: Cushin ...	Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHE ...	Corcept Therapeutics Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	75	Phase 2;Phase 3	United States;Hungary;Canada;Spain;Poland;Romania;Austria;Israel;Bulgaria;Netherlands;Germany;Italy
10	EUCTR2018-001616-30-ES (EUCTR)	14/02/2020	10/01/2020	Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatmen ...	An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Sig ...	Endogenous CushingSyndrome MedDRA version: 20.0;Level: LLT;Classification code 10011657;Term: Cushin ...	Product Code: CORT125134 INN or Proposed INN: Relacorilant Other descriptive name: (R)-(1-(4-FLUOROPHE ...	Corcept Therapeutics Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	75	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Italy;Germany;Netherlands;Bulgaria;Israel;Austria;Romania;Spain;Poland;Canada;Hungary;United States

First Previous1 2 3 4 5…21Next Last